
Inotiv, Inc.
- Jurisdiction
United States - LEI
549300FH5Z13X0Q5SK81 - ISIN
US45783Q1004 (NOTV )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
6
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. Read full profile
Fundamentals
- Net revenue
€431.00M - Gross margin
20.6% - EBIT
-€11.23M - EBIT margin
-2.6% - Net income
-€67.35M - Net margin
-15.6%
Statement period: - (published )
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Neff R Matthew | N/A |
|
|
|
|
Neff R Matthew | N/A |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: August 7, 2025 (Q3 2025)